The U.S. Food and Drug Administration (FDA) has officially approved the Wegovy pill, marking the first oral GLP-1 medication for weight management available in the United States. This groundbreaking approval allows patients to take a daily pill as an alternative to previous injection methods. Wegovy, produced by Novo Nordisk, is expected to significantly widen access to obesity treatment and potentially redefine the obesity drug market. As competition in this field heats up, with other contenders like Eli Lilly also filing for new weight-loss drugs, Novak Nordisk is poised for a strong launch following this landmark approval.